Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | NCEH1 | Q6PIU2 | 2/20 | 0.43 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5016692 | 1.00 | TRPV1 (0.47) | TRPV1PPARGPPARANCEH1LTA4H | |
| SCHEMBL5015897 | 1.00 | TRPV1 (0.47) | TRPV1PPARGPPARANCEH1LTA4H | |
| SCHEMBL5015956 | 0.88 | PPARA (0.53) | PPARGPPARALTA4H | |
| SCHEMBL14232241 | 0.83 | TRPV1 (0.52) | TRPV1PPARGPPARANCEH1LTA4H | |
| SCHEMBL5014941 | 0.82 | KAT8 (0.53) | TRPV1PPARAPTGS2KAT8 | |
| SCHEMBL181330 | 0.81 | PPARG (0.53) | TRPV1PPARGPPARAPTGS2S1PR1 | |
| SCHEMBL13422245 | 0.76 | THRB (0.55) | TRPV1PPARGPPARAS1PR1S1PR3 | |
| SCHEMBL7252668 | 0.76 | TRPV1 (0.56) | TRPV1PPARGPPARALTA4HKAT8 | |
| SCHEMBL7246712 | 0.76 | TRPV1 (0.56) | TRPV1PPARGPPARALTA4HKAT8 | |
| SCHEMBL21878246 | 0.76 | TRPV1 (0.53) | TRPV1PPARGPPARALTA4HKAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449608-B2 | Naphthol derivative and charge control agent comprising the same | UENO FINE CHEMICALS INDUSTRY, LTD. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20050119487-A1 | Naphthol derivative and charge control agent comprising the same | KABUSHIKI KAISHA UENO SEIYAKU OYO KENKYUJO (JP) | 2005-06-02 | — | — | US | disclosed |
| EP-1462440-A1 | NAPHTHOL DERIVATIVE AND CHARGE CONTROL AGENT COMPRISING THE SAME | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo (JP) | 2004-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119487-A1 | Naphthol derivative and charge control agent comprising the same | CECR2, PEF1, NAP1L1 | TRPV1 891/4885PPARG 1893/4885PPARA 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.